Following the launch of two new therapies since last year, Japan has seen fresh moves in drug development for amyotrophic…
ORGANIZATION
Medical Advocacy Group Condemns Plan to Remove Coverage for OTC-Like Drugs
The Japan Federation of Democratic Medical Institutions (Min-Iren) said in a statement on April 16 that it strongly opposes the potential exclusion of OTC-like medicines from national insurance coverage. The advocacy group of medical and long-term care facilities argued that…
To read the full story
Related Article
- Topic of OTC-Like Drugs Dropped from 3-Party Talks: Ishin
May 27, 2025
- Impact of Nationwide Implementation of Regional Formularies “Difficult to Estimate”: MHLW Official
May 23, 2025
- OTC-Like Drug Is Hardest Topic in Tripartite Social Security Talks: Japan PM
May 22, 2025
- Regional Formulary Push Pops Up from Ishin at 3-Party Talks
May 16, 2025
- Ruling Bloc, Ishin Reach No Deal on Coverage of OTC-Like Drugs
May 8, 2025
- MHLW to Present Estimate on Coverage Removal of OTC-Like Meds at 3-Party Talks
April 24, 2025
- Ruling Coalition Wary of Scrapping Coverage for OTC-Like Drugs
April 21, 2025
- Scrap Coverage for OTC-Like Drugs with Same APIs and Dose as OTC Meds: Nippon Ishin
April 14, 2025
- 3-Party Talks Fail to Reach Specifics on OTC-Like Drugs
April 4, 2025
- Three-Party Talks to Be Held on Health Coverage of OTC-Like Drugs: Minister
March 4, 2025
ORGANIZATION
- Revamp Drug Price System to Make Room for Wage Hikes: Labor Union
May 29, 2025
- JPMA Revises Definition of Promotion in Code of Practice
May 27, 2025
- FPMAJ Sets Out on New Lobbying Push with Astellas’ Yasukawa as New Chief
May 23, 2025
- Takeda’s Miyabashira Elected as New JPMA President
May 23, 2025
- At JPA’s Behest, FPMAJ Asks Members to Align Packaging with Approved Dosages
May 19, 2025
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…